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ABSTRACT
Telomere and Telomerase have recently been explored as anti-aging and anti-
cancer drug targets with only limited success. Previously we showed that the Chinese 
herbal medicine Tianshengyuan-1 (TSY-1), an agent used to treat bone marrow 
deficiency, has a profound effect on stimulating Telomerase activity in hematopoietic 
cells. Here, the mechanism of TSY-1 on cellular Telomerase activity was further 
investigated using HL60, a promyelocytic leukemia cell line, normal peripheral blood 
mononuclear cells, and CD34+ hematopoietic stem cells derived from umbilical cord 
blood. TSY-1 increases Telomerase activity in normal peripheral blood mononuclear 
cells and CD34+ hematopoietic stem cells with innately low Telomerase activity but 
decreases Telomerase activity in HL60 cells with high intrinsic Telomerase activity, 
both in a dose-response manner. Gene profiling analysis identified Telomerase reverse 
transcriptase (TERT) as the potential target gene associated with the TSY-1 effect, 
which was verified by both RT-PCR and western blot analysis. The β-galactosidase 
reporter staining assay showed that the effect of TSY-1 on Telomerase activity 
correlates with cell senescence. TSY-1 induced hypomethylation within TERT core 
promoter in HL60 cells but induced hypermethylation within TERT core promoter 
in normal peripheral blood mononuclear cells and CD34+ hematopoietic stem cells. 
TSY-1 appears to affect the Telomerase activity in different cell lines differently and 
the effect is associated with TERT expression, possibly via the methylation of TERT 
promoter.
INTRODUCTION
Over the past two decades, there has been intense 
interest in the study of the regulation of Telomerase, which 
is an RNA-dependent DNA polymerase. Telomerase 
contains a short RNA template complementary to 
the DNA Telomere sequence, as well as a catalytic 
protein with Telomerase reverse transcriptase activity. 
Telomerase is responsible for maintaining Telomere 
length. Earlier studies demonstrated that over 80% of all 
cancer types showed increased Telomerase activity and 
hence, increased Telomere length in cancer cells over 
their normal cell counterparts [1]. This together with 
activating oncogenes / deactivating tumor suppressor 
genes result in the dysregulation of tumor cell growth and 
proliferation [2, 3]. Due to its significant role in cancer 
biology, a considerable amount of effort has been devoted 
to developing specific inhibitors of Telomerase activities 
in order to develop targeted anti-cancer drugs. Thus far, 
      Research Paper
Oncotarget7978www.impactjournals.com/oncotarget
these efforts have resulted in only limited success. This is 
partly due to the fact that cellular Telomerase homeostasis, 
including Telomerase activity and Telomere length, 
is regulated by a complex network of genes that have 
interconnected signals.
On the contrary, there have also been attempts 
to develop approaches to increase cellular Telomerase 
activity, as an auspicious anti-aging strategy [4, 5], or as 
a counteractive measure for some disease conditions such 
as bone marrow failure that are associated with decreased 
Telomerase activity. In fact, aplastic anemia (AA), the 
most severe form of bone marrow failure, is found to 
have a mutated telomerase gene resulting in the loss of 
Telomerase activity in hematopoietic cells in about one 
third of all cases. Even in those AA cases without the 
telomerase gene mutation and in cases of myelodysplastic 
syndrome (MDS), another form of severe bone marrow 
deficiency, decreased Telomerase activity in hematopoietic 
cells has also been seen [6–8].
Therefore, it seems that any efforts to target 
Telomerase activity, by either inhibition or stimulation, 
should be carefully tailored to an individual organ, system 
or cell type. Also agents that regulate the homeostasis 
of Telomerase activity may be superior to agents that 
drive the activity in only one direction, which may result 
in untoward side effects. In this study, we found that a 
Chinese herbal medicine, TSY-1, has a property that 
regulates Telomerase homeostasis. TSY-1 has been used to 
treat patients with AA for many years with some success, 
though definitive clinical trial data is not available at this 
time. Previously, two in vivo bone marrow deficiency 
mouse models, one induced with chemicals and the other 
induced with immune-suppression and radiation treatment, 
have both demonstrated strong bone marrow recovery 
after TSY-1 treatment. These studies appeared to reflect 
an effect of TSY-1 on modulating endogenous Telomerase 
activity [9–12]. Our current study demonstrated that TSY-
1 has profound effects on maintaining the homeostasis of 
Telomerase activity: it inhibits the Telomerase activity in 
cancerous HL60 cells, which has high intrinsic Telomerase 
activity, whereas it increases Telomerase activity in normal 
peripheral blood mononuclear cells (PBMCs) and CD34+ 
hematopoietic stem cells (HSCs) derived from umbilical 
cord blood. Further, we demonstrated that such effects 
are associated with the epigenetic regulation of TERT 
promoter region.
RESULTS
TSY-1 inhibited Telomerase activity in HL60 
cells but increased Telomerase activity in PBMCs 
and HSCs
To explore that TSY-1 has opposite effects on 
Telomerase activity between cancerous cells and normal 
cells, we chose human leukemia cells HL60, which was 
known to have high intrinsic Telomerase activity [12], 
and healthy donor-derived human PBMCs as well as 
core blood CD34+ HSCs with low intrinsic Telomerase 
activity. The effect of TSY-1 on Telomerase activity was 
tested using a quantitative telomeric repeat amplification 
PCR assay. Treatment cells were treated with 31.2 μg/ml 
and 62.5 μg/ml of TSY-1 drug for 24 hours and compared 
to the untreated control cells. As represented in Figure 1, 
we detected strong innate Telomerase activity in HL60 
cells. With the treatment of TSY-1, the Telomerase 
activity decreased significantly in HL60 cells. However, 
TSY-1 treatment increased Telomerase activity in PBMCs 
and HSCs compared to the untreated control. Both of 
the changes (decreased Telomerase activity in HL60 
and increased Telomerase activity in PBMCs and HSCs) 
showed a dose-response relationship. Taken together, 
these data confirm that TSY-1 has an opposite effect on 
leukemia cells with intrinsically high Telomerase activities 
(inhibitory) and normal blood mononuclear and stem cells 
with low Telomerase activities (stimulatory).
TERT was identified as a target gene for  
TSY-1 activity
The differential effect of TSY-1 on Telomerase 
activity in these cell models provided opportunities to 
identify potential target genes associated with TSY-1 
activity (Figure 2). Using Affymetrix GeneChip Human 
Transcriptome Array system, we screened the entire 
genome in order to identify potential target genes that are 
associated with TSY-1-induced Telomerase modulation. 
The heat maps in Figure 3 demonstrate that both HL60 
cells and PBMCs treated with TSY-1 62.5 μg/ml had 
a greater difference in gene expression compared to 
their untreated control cells. A total of 764 genes were 
differentially expressed between HL60 control cells 
and TSY-1 62.5 μg/ml treated cells, and 501 genes were 
differentially expressed between control PBMCs and TSY-
1 62.5 μg/ml treated cells. TERT gene expression showed 
an opposite fold change after TSY treatment between 
HL60 cells and PBMCs (-1.82 VS 1.21), similar to the 
change pattern of Telomerase activity observed above. 
We then further identified genes that showed opposite 
expression patterns between HL60 cells versus PBMCs 
as well as HSCs, focusing on Telomere-associated 
genes. We performed a human Telomeres & Telomerase 
RT² profiler™ PCR array analysis, which profiled the 
expression of 84 key genes central to Telomere replication, 
maintenance, regulation and Telomere-associated 
complexes. The results were shown in Table 1. The gene 
target that showed the most prominently differential effect 
between HL60 (down regulation) and PBMCs / HSCs (up 
regulation) is, again, the TERT gene.
To verify this result, a qPCR analysis was performed 
on TERT gene expression in three cell lines with and 
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without TSY-1 treatment. As shown in Figure 3, our results 
confirmed that TSY-1 had an opposite effect on TERT 
gene expression between HL60 cells and PBMCs / HSCs. 
The 62.5 μg/ml concentration of TSY-1 drug had the 
maximum effect on TERT gene expression. Western blot 
combined with immunoprecipitation showed that TERT 
protein level in HL60 cells decreased significantly after 
TSY-1 treatment by a dose-dependent manner. In contrast, 
TERT protein level was elevated in treated PBMCs and 
HSCs compared with the untreated controls, although 
no significant difference existed between the control and 
treated HSCs (Figure 3). Therefore, in corroboration with 
the results from the Telomerase activity assays, it seems 
that the effect of TSY-1 on Telomerase activity may be 
mediated by TERT gene expression.
TSY-1 treatment induced cell senescence in 
HL60 cells but not in PBMCs and HSCs
Cell populations that stop growing can exhibit 
markers of senescence, including senescence-associated 
β-galactosidase staining. Cells stained dark blue are 
considered senescent cells, because the β-galactosidase 
activity was detected. Under the microscope field, 
we found that the total number of healthy HL60 cells 
significantly decreased after TSY-1 treatment, whereas 
the number of healthy PBMCs and HSCs increased. After 
treatment, the dark blue staining became larger and denser, 
and the percentage of labeling cells also increased in HL60 
cells but not in PBMCs and HSCs (Figure 4).
Demethylation / hypermethylation within TERT 
promoter positively related to gene expression 
after TSY-1 treatment
Transcriptional regulation is a critical process 
to control TERT gene expression. In this study, the 
TERT gene expression changed within 24 hours, which 
underlines the possible role of transcriptional regulation. 
To confirm this, we focused on the epigenetic regulation 
within TERT core promoter region. Previous studies have 
chosen different regions of TERT promoter to explore the 
epigenetic regulation. Pettigrew et al. reported differential 
TERT promoter methylation and response to Decitabine 
in 20 CpG sites in acute myeloid leukemia cell lines [13]. 
We amplified a 185bp DNA fragment through bisulfite 
specific PCR. Then, through pyrosequencing, we analyzed 
the methylation patterns of 22 CpG sites in a region 
spanning 143bp (Figure 5A). Among the 3 untreated cell 
lines, the methylation levels of all 22 CpG sites in HL60 
cells were remarkably higher than those of PBMCs and 
HSCs. The percentage of methylation in each CpG site 
Figure 1: The changes of telomerase activity following TSY-1 treatment in HL60 cells, PBMCs and HSCs. We detected 
telomerase activity using TRAP. Telomerase is a heat-sensitive enzyme. As a negative control, every sample extract to be evaluated was 
also tested for heat sensitivity. Thus, analysis of each sample consists of two assays: one with a test extract and one with a heat-treated 
test extract. Gel pictures showed that TSY-1 treatment decreased telomerase activity in HL60 cells but increased telomerase activity in 
PBMCs and HSCs. * P < 0.05, compared to untreated control, t-test. PBMC: normal peripheral blood mononuclear cells, HSCs: CD34+ 
hematopoietic stem cells, TRAP: PCR-based telomeric repeat amplification protocol.
Oncotarget7980www.impactjournals.com/oncotarget
Figure 2: Diagram of strategies identifying target genes associated with TSY-1 activity.
gradually declined from upstream towards downstream 
(Figure 5B). Demethylation in HL60 cells (16 sites) and 
hypermethylation in PBMCs (17 sites) / HSCs (22 sites) 
that TSY-1 treatment induced were observed in a dose-
response manner. In particular, 12 sites showed an opposite 
methylation pattern between HL60 cells (downregulated) 
and PBMCs / HSCs (upregulated), which were associated 
with concomitant decrease of TERT expression in HL60 
cells and increase of TERT expression in PBMCs and 
HSCs (Figure 5C). Most of these sites were located in 
the hypomethylated downstream area. Among these 3 
cell lines, we also observed that the most prominent 
differential effect of TSY-1 treatment on methylation was 
in HSCs.
DISCUSSION
More than 80% of cancers have increased 
Telomerase activity [1], and Telomerase has served as 
an attractive target for anti-cancer drug development. 
Strategies including antisense oligonucleotide 
inhibitors, small molecular inhibitors, Telomerase-based 
immunotherapies and Telomerase-based oncolytic gene 
therapies have been explored [14, 15]. Clinical studies 
showed that when combining anti-Telomerase treatment 
with traditional therapies such as chemotherapy or 
radiotherapy, some success has been achieved. However, 
the overall benefit is rather limited. Part of the reasons 
may be due to the fact that Telomerase activity is rather 
dynamic and may be multi-directional during the course 
of cancer progression. It has been observed that shortened 
Telomeres not only limit the proliferative potential but 
also can be associated with increased tumor initiation, 
and promote chromosomal instability [16, 17]. This 
complex activating/repressive process makes it difficult 
to use Telomerase activator/inhibitor as a single target to 
regulate the cell growth and cancer development alone. 
Furthermore, as Telomerase inhibition may result in the 
inhibition of normal functions, especially hematopoietic 
stem cell functions, such a strategy may result in untoward 
side effects. Myelosuppression, anemia, neutropenia and 
thrombocytopenia have been commonly observed with the 
findings of recent clinical trials [18–20].
Likewise, because there are disease conditions that 
are associated with decreased or abnormal Telomerase 
function, some also attempt to develop approaches to 
increase Telomerase activity as an anti-aging strategy. 
Currently, the most studied method to extend Telomere 
is viral delivery [5]. Recently, Ramunas et al. delivered 
modified mRNA encoding TERT to human fibroblasts 
and myoblasts and found that this delivery could extend 
Telomeres rapidly and increase cell proliferation [21].
However, as exciting as the above target approaches 
may be, in theory, one may expect untoward side effects 
with such one directional approaches [22]. Application 
of Telomerase inhibitors in cancer patients may result in 
inhibition of bone marrow, whereas increased Telomerase 
activity may cause cell immortalization and promote 
carcinogenesis. The findings of increasing cancer risk 
from previous studies in animal models make Telomerase 
activators difficult to justify for their use in clinical 
practice [23–25].
TSY-1, a Chinese herb regimen, is rather unique. 
Our study shows that at least in hematopoietic cells, it 
has an effect of maintaining Telomerase homeostasis, 
i.e., inhibits Telomerase activity in intrinsically high 
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Figure 3: TERT gene and protein expression among different treatment and cells. Heat map analysis of control versus TSY-1 
treatment in HL60 cells (A) and PBMCs (B). A. up- and downregulation of the 765 genes that are differentially expressed between HL60 
control and HL60 TSY-1 treatment. To generate the heat map, the data from all 6 samples is used to generate a standardized mean of 0 and 
a standard deviation of 1. Each sample is then compared to this mean to determine up or downregulation of the gene. The map shows that 
HL60 control and HL60 TSY-1 62.5 μg/ml are very different in gene expression. Note that PBMC control is very different (almost like 
opposites) compared to HL60 control. This indicates that a different set of genes are differentially expressed in the PBMCs. B. up- and 
downregulation of the 501 genes that are differentially expressed between PBMC control and PBMC TSY-1 treatment. The map shows 
the PBMC control and PBMC TSY-1 62.5 μg/ml are very different in gene expression. Note that PBMC control looks very different from 
HL60 control.
qPCR analysis of TERT gene expression in HL60 cells C., PBMCs D. and HSCs E. TERT gene expression was measured by qPCR 
analysis. β-actin served as a reference gene for each triplicate set of reaction. Compared with the untreated control, TERT gene expression 
decreased in HL60 cells but increased in PBMCs and HSCs. * P < 0.05, compared to untreated control, t-test.
TERT protein expression in HL60 cells F., PBMCs G. and HSCs H. The cells were treated by the TSY-1 of different concentration (31.2 
μg/ml and 62.5 μg/ml). Cell lysates were immunoprecipitated with TERT antibody followed by SDS-PAGE analysis. Immunoblot picture 
shows TSY-1 treatment decreased TERT protein level in HL60 cells but not in PBMCs and HSCs. * P < 0.05, compared to untreated control, 
t-test. PBMC: normal peripheral blood mononuclear cells, HSCs: CD34+ hematopoietic stem cells.
expression malignant HL60 cells, whereas increases 
Telomerase activity in normal PBMCs and HSCs in a 
dose-response manner. Unlike most Chinese medicine, 
which is typically prepared by boiling, TSY-1 is extracted 
through a distillation process of multiple Chinese 
herbs: almond, pericarpium citri reticulatae viride, 
mangnolia officinalis, frankincense, and schisandra 
chinensis. Although it is difficult to identify a single 
effective constituent from multi-herbs, the standardized 
preparation can ensure consistencies with respect to 
concentration of active ingredients [26]. Recent studies 
utilizing mouse-models with both chemical-induced and 
radiation-induced bone marrow failure showed that the 
mice with bone marrow failure treated with TSY-1 had 
significant recovery of hematopoietic cells in both bone 
marrow and peripheral blood. In addition, TSY-1 induces 
extramedullary hematopoiesis in multiple organ systems 
including both liver and spleen and also specifically 
increases the number of CD4+/CD8- T cells and CD34+ 
cells (9, 10).
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TSY-1 has been used in China for many years to 
treat AA and MDS. It is not until recently that studies 
have shown that bone marrow deficiency of MDS and 
AA are associated with Telomerase abnormality, whereas 
about one-third of congenital AA harbors mutations of the 
TERT gene resulted in loss of Telomerase activity [27]. In 
our previous study, we found that TSY-1 has the ability to 
recover bone marrow deficiency in in vivo animal model 
studies [12], and such an effect is associated with the 
Telomerase activity. Time course experiment on cultured 
cell lines showed the effect can be seen within 6-hour 
treatment. But we have not tested the effect of TSY-1 on 
Telomerase activity after removal of the TSY-1 treatment. 
It has been shown that a number of compounds can 
induce changes of Telomerase activity [28]. For example, 
hormones such as estrogen and testosterone and some 
Table 1: TSY-1 induced changes of expression in telomere associated genes in HL-60, PBMCs and HSCs
Telomere Maintenance Telomere Associated Complex Telomere Regulation Other Telomerase-associated Genes
Gene Target HL60 PBMCs HSCs Gene Target HL60 PBMCs HSCs Gene Target HL60 PBMCs HSCs Gene Target HL60 PBMCs HSCs
DCLRE1C -1.37 1.15 -1.33 RAP1A 1.11 -1.10 1.10 TGFB1 1.32 -1.08 1.12 ATM -1.28 1.14 1.34
HSPA1L 4.52 5.74 2.85 ACD -1.67 1.55 1.49 SSB -1.76 1.04 1.17 CDK2 -2.59 1.06 1.00
MRE11A -2.14 1.14 1.08 POT1 1.01 1.38 -1.32 SP1 1.07 1.05 -1.06 CHEK1 -1.73 1.83 -1.48
NBN 1.01 1..59 -1.05 TINF2 1.08 -1.01 -1.73 SART1 -1.24 1.02 1.37 CHEK2 -2.10 1.06 -1.12
PARP1 -2.22 1.10 -1.28 TERF1 -1.02 -1.57 -1.26 RB1 1.14 1.03 1.39 HAT1 -1.36 1.34 1.20
PIF1 1.36 1.69 2.05 TERF2 -1.13 1.11 1.08 RAPGEF1 1.25 -1.01 1.59 HNRNPA2B1 -2.08 1.11 1.03
PRKDC -2.27 -1.15 -1.46 GAR1 -1.96 1.20 -1.47 RASSF1 1.96 1.23 1.05 HNRNPD -1.47 1.21 1.08
PTGES3 -1.55 1.75 2.48 NHP2 -2.21 -1.21 -1.37 TP53 - 1.04 -1.14 HSP90AA1 -1.30 2.34 2.61
RAD50 -1.23 -1.12 1.05 NOP10 1.01 1.55 1.14 DCLRE1B -1.76 1.01 -1.13 NCL -2.08 1.05 -1.26
RFC1 -1.12 -1.05 -1.44 TERT -5.55 1.69 8.12 KRIT1 -1.37 -1.07 -1.08 OBFC1 1.11 -1.60 -2.00
SMG6 1.11 -1.07 1.24 DKC1 -1.24 -1.17 -1.24 MYC -4.58 -1.40 -1.32 PURA 1.64 1.31 2.35
TNKS2 -1.23 1.13 -1.06 EME1 -1.07 -1.89 1.13 SMAD3 1.25 1.69 8.12 RAD17 -1.13 1.05 1.19
RTEL1 -2.34 1.05 1.22 MSH2 -1.57 -1.17 -1.35 ABL1 -1.27 1.18 -1.24 RIF1 -1.30 1.11 -1.56
TEP1 1.08 1.50 1.29 MSH3 -1.52 1.07 -1.22 AKT1 -1.65 1.12 -1.08 SIRT2 -1.53 1.19 1.24
TNKS 1.03 -1.14 -1.15 MUS81 1.26 1.05 1.21 ATP5C1 -1.37 1.08 1.17 SIRT6 -1.34 1.13 1.38
POT1 1.01 1.38 -1.32 PLK1 -1.12 -1.75 -1.40 BCL2 -1.84 1.61 -1.28 SUN1 1.49 1.34 2.55
TINF2 1.08 -1.01 -1.73 SLX4 -1.06 -1.10 1.04 EGF 1.67 - 2.32 TP53BP1 -1.86 -1.08 -1.17
TERF1 -1.02 -1.57 -1.26 ERCC1 1.05 1.28 1.19 IGF1 - - 4.51
ERCC4 -1.05 1.05 1.16 ERCC4 -1.05 1.05 1.16 KRAS -1.30 1.20 -1.07
TERF2 -1.13 1.11 1.08 TERF2 -1.13 1.11 1.08 MEN1 -1.99 1.02 -1.20
TERF2IP -1.02 1.01 1.10 TERF2IP -1.02 1.01 1.10 PAX8 -1.24 -1.26 2.48
DKC1 -1.24 -1.17 -1.24 PINX1 -1.52 1.09 -1.03
TERT* -5.55 1.69 8.12 PPARG 7.30 -3.43 3.98
MYC -4.58 -1.40 -1.32 PPP2R1A -1.20 1.28 1.20
ERCC1 1.05 1.28 1.19 PPP2R1B -1.42 1.41 -1.32
ACD -1.67 1.55 1.49 PRKCA 1.95 -1.43 1.91
BLM -1.97 1.17 1.13 PRKCB 1.93 1.00 1.21
The gene target that shows the most prominent differential effect between HL-60 (down regulation) and PBMCs / HSCs 
(up regulation) is TERT gene. Others (ACD, BLM, ATP5C1, BLM, CDK2, ERCC4, HAT1, HNRNPD, HSP90A1, 
MRE11A, PPP2R1A, PTGES3, RAD17, RTEL1, SART1, and SSB), have the same direction, but with minimal effect 
(mostly <2-fold change). PBMC: normal peripheral blood mononuclear cells, HSCs: CD34+ hematopoietic stem cells.
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growth factors increase the Telomerase activity, whereas 
differentiation agents such as retinoic acid have opposite 
effect. We previously tested granulocyte-macrophage 
colony-stimulating factor (GM-CSF), a growth factor 
stimulating hematopoietic cell proliferation and 
differentiation, which did not show effects on Telomerase 
activity when used alone (data not shown). Similar result 
was reported by others [29]. It should be noted that we 
used different batch of TSY-1 in the current study with the 
crude drug concentration of 0.62 g/ml, which was twice 
higher than what was used in the previous study (0.31 g/
ml) [12]. Therefore, we used higher dilutions in the current 
study whereas the final effective concentrations of TSY-1 
drug were similar.
By comparing global gene expression patterns 
of HL60, PBMCs and HSCs, we identified that the 
potential target gene of TSY-1 activity is the TERT gene. 
TERT is the major regulatory component of Telomerase 
activity [30]. Our results of TERT gene expression were 
consistent with the changes of Telomerase activity, which 
were further proved by the western blot analysis on TERT 
protein expression. Our β-galactosidase staining showed 
a distinctive change of cell senescence between HL60 
and PBMCs / HSCs. More studies are still needed to 
determine whether these changes were directly modulated 
by TERT expression [31–34]. It is worth noting that we 
see a significant reduction of cell proliferation in HL60 
cells but not in PBMCs and HSCs, further supporting the 
inhibiting effect of TSY-1 on human leukemia cells.
The observed modulating effect of TSY-1 on 
Telomerase activity in different cell systems suggests 
that TSY-1 may regulate Telomerase activity through 
epigenetic mechanisms, probably through TERT. Indeed, 
TERT core promoter contains abundant CpG sites. Several 
important transcription binding sites have also been 
identified [35–37]. E-box (located at -165 and +44 region) 
is considered as a binding site that can interact with Myc 
family oncogenes and may activate TERT transcription 
[38, 39]. GC boxes are other important binding sites for 
zinc finger transcription factor Sp1, which may contribute 
in maintaining the activity of the TERT promoter[40]. 
Generally, it is recognized that methylation of the CpG 
sites in the promoter region will inhibit transcription and 
result in gene silencing [41]. However, in terms of the 
TERT promoter, the examination of methylation status of 
CpG sites and TERT expression are rather controversial 
Figure 4: Effects of TSY-1 on beta-galactosidase labeling in HL60 cells, PBMCs and HSCs. Cells were harvested and 
fixed, followed by cytospin and staining with senescence beta-galactosidase staining kit. Remarkably, the total number of healthy HL60 
cells decreased after TSY-1 treatment, which did not happen in PBMCs and HSCs. The histogram shows the percentage of labeling cells 
following TSY-1 treatment increased in HL60 cells but decreased in PBMCs and HSCs. * P < 0.05, compared to untreated control, t-test. 
PBMC: normal peripheral blood mononuclear cells, HSCs: CD34+ hematopoietic stem cells.
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Figure 5: Distinct methylation profiles among different cells and treatment. A. DNA fragment in TERT core promoter region 
was amplified. The underlined region was analyzed by pyrosequencing, which included 22 CpG sites. B. The percentage of methylation 
across 22 CpG sites among untreated HL60 cells, PBMCs and HSCs. C. Heatmap of DNA methylation profiling of TERT core promoter. 
The bottom blue-red scale bar refers to the degree of methylation measured by pyrosequencing. CpG 1, 8, 10, 11, 13, 16, 17, 18, 19, 20, 21 
and 22 showed an opposite change of methylation pattern in a dose-response manner between HL60 cells (downregulated) and PBMCs / 
HSCs (upregulated). PBMC: normal peripheral blood mononuclear cells, HSCs: CD34+ hematopoietic stem cells.
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[42, 43]. Recently, studies indicated hypermethylation 
of the TERT promoter ubiquitously exists in highly 
proliferative cancer cells and correlates with increased 
Telomerase activity. On the contrary, many low 
proliferative normal cells demonstrate a hypomethylation 
in the TERT promoter region with decreased Telomerase 
activity [44].
We analyzed 22 CpG sites within the TERT core 
promoter region through pyrosequencing and found that 
Leukemia cell line HL60 demonstrated a significant 
hypermethylation within the TERT promoter compared to 
that of normal blood cells PBMCs and HSCs, supporting 
a positive relationship between hypermethylation in TERT 
promoter and Telomerase activity. After treatment, multiple 
CpG sites show changes of methylation percentage in 
parallel with TERT expression. This intriguing finding 
provides the foundation for the hypothesis that TSY-1 may 
exert the effect of maintaining homeostasis of Telomerase 
activity by epigenetic regulation. Yet more in-depth studies 
are still needed to elucidate exactly how TSY-1 affects the 
CpG island methylation. Further, it will be interesting to 
compare the effects of TSY-1 on TERT expression with 
other Telomerase inhibitors and activators, and also study 
the effect of TSY-1 on carcinogenesis.
In summary, TSY-1 appears to affect the Telomerase 
activity in different cell lines differently: inhibits 
Telomerase activity in intrinsically Telomerase-high 
leukemic HL60 cells but increases Telomerase activity in 
innately Telomerase-low normal PBMCs and HSCs. This 
effect appears to be mediated by methylation of the TERT 
promoter. The strategy of maintaining the homeostasis 
of Telomerase activity may have significant impact in 
developing approaches for Telomerase-based target 
treatment of bone marrow deficiency and cancer. Whether 
such an effect relates to the potential clinical benefit for 
patients remains to be tested in further studies.
MATERIALS AND METHODS
Cell culture, treatment and Telomerase 
activity assay
Human leukemia cells HL60 were obtained from 
American Type Culture Collection (ATCC, USA) 
and grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% (v/v) fetal bovine serum 
(FBS) and 1% (v/v) streptomycin/penicillin (S/P). The 
human normal PBMCs and core blood derived CD34+ 
HSCs were isolated from healthy donors in the Center 
for AIDS Research virology core laboratory (University 
of California, Los Angeles). PBMCs were suspended in 
RPMI 1640 with 10% Human Serum AB. HSCs cells 
were grown in StemPro-34 Medium containing nutrient 
supplement, L-Glutamine (2mM), cytokines SCF (100 ng/
mL), IL-3 (50 ng/mL) and GM-CSF (25 ng/mL). These 
cells were maintained at 37.0°C with 5% CO2. For all cell 
lines, medium was replaced every 2 to 3 days depending 
on cell density, which was maintained around 1 × 106 
viable cells/ml before TSY-1 treatment.
TSY-1 liquid of 10ml/vial, batch No. YZ130506, 
with a content of crude drug of 0.62 g/ml, with the 
purified drug concentration of 1mg/ml, was provided by 
Beijing Boyuantaihe Biological Technology Co., Ltd. 
The cultured cells were treated with 1/32 (31.2 μg/ml) 
and l/16 (62.5 μg/ml) dilutions of TSY-1 stock solution, 
which was determined by previous cell proliferation 
assay, for 24 hours prior to harvesting for the analysis 
of Telomerase activity and TERT expression. While the 
actual active ingredient(s) is not known at the moment, gas 
chromatography analysis has performed and identified a 
main peak that remains to be characterized. Cells cultured 
in medium treated with 0.01% Tween solution (the solvent 
of TSY-1 drug) were served as a TSY-1 untreated control.
Enzymatic activity was detected by the PCR-based 
telomeric repeat amplification protocol (TRAP), using the 
Quantitative Telomerase Detection Kit and following the 
manufacturer’s instructions (US Biomax). As a negative 
control, every sample extract to be evaluated was also 
tested for heat sensitivity. Heat treatment was performed 
by incubating samples at 85°C for 10 minutes prior to the 
Telomerase activity assay. A dilution series of TSR control 
template was prepared in lysis buffer to serve as a standard 
curve. PCR was set at: 35 cycles of 94°C 30 s, 59°C 30 
s and 72°C 30 s. The quantity of Telomerase substrate 
produced in each well was determined from a linear plot 
of the log10 of the quantities of the TSR control template 
standards versus the Ct values for their wells. Telomerase 
activity was determined as the relative ratios of the mean 
quantity of Telomerase substrate in each TSY treated 
sample to the mean quantity of Telomerase substrate in 
the untreated control sample. PCR products were also run 
on a 10% polyacrylamide gel in TBE stained with SYBR 
Gold Nucleic Acid Gel Stain.
RNA extraction, gene expression analysis and 
quantitative PCR
Total RNA was extracted and purified from HL60, 
PBMCs and HSCs using an RNeasy Miniprep Kit 
(Qiagen). The effect of TSY-1 on gene expression profiles 
of HL60 cells and PBMCs was tested using the Affymetrix 
GeneChip® Human Transcriptome Array (HTA) 2.0 
system. Total RNA samples were submitted to the UCLA 
Department of Pathology and Laboratory Medicine 
Clinical Microarray Core for processing. The Affymetrix 
WT PLUS Reagent Kit was used to prepare the RNA for 
hybridization to the HTA. Data analysis was performed 
using the Affymetrix Expression Console software and 
Transcriptome Analysis Console software. The Human 
Telomeres & Telomerase RT² Profiler PCR Array was 
also used for the analysis of Telomere-associated gene 
expression (Qiagen).
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TERT gene expression between control and 
TSY-1 treated samples was verified via qPCR using 
iTaq Universal SYBR Green Supermix (BIO-RAD) in 
iCycler iQ™ Real-Time PCR Detection System (BIO-
RAD). Reverse transcription reaction was set at 42 °C 
for 90 min and inactivation at 85 °C for 5 min, followed 
by the cDNA amplification reaction: 95 °C 5min, 40 
cycles of 95 °C for 30 s, 59 °C for 30 s and 72 °C for 
45 s in 20μl reaction mixtures. Data acquisition was 
set at the chain extension step and the melt curve data 
collection analysis was performed between 55 and 
95°C, with 0.5°C increments. Forward primer was 
5'-GAGCTGACGTGGAAGATGAG-3' and reverse 
primer was 5'-CAGGATCTCCTCACGCAGAC-3'. Beta-
actin was served as a reference gene for each triplicate 
set of reaction repeated three times. Results shown here 
are the mean normalized values of cDNA levels with the 
reference gene.
Western blot analysis
Protein immunoprecipitation combined with 
Western blot was used to measure the expression of 
TERT protein. The control and treated cells were lysed 
in RIPA buffer. The extracts were incubated with human 
TERT antibody (Santa Cruz Biotechnology) and 20 μl of 
protein A/G Plus-Agarose (Santa Cruz Biotechnology). 
After washing and boiling, the samples were centrifuged 
to pellet the agarose beads, followed by SDS-PAGE 
analysis of the supernatant. To ensure use of equal 
amounts of protein per sample, blots were performed 
before immunoprecipitation experiments using Beta-
actin. Cell protein extracts were resolved by SDS-PAGE 
(8%). The proteins were transferred onto a nitrocellulose 
membrane and immunoblotted with the primary antibody 
(1:2000) and secondary antibody (1:5000). After extensive 
washing, membranes were reacted with ECL detection 
reagents immediately prior to autoradiography. The 
relative levels of TERT protein were determined by 
scanning densitometry.
DNA extraction, bisulfite treatment and 
methylation analysis
Genomic DNA was extracted from cells using the 
QIAamp® DNA Mini Kit (Qiagen). After the Nanodrop 
measured the concentration of DNA, the DNA stock 
solution was stored at -80ºC until use. The extracted DNA 
samples were bisulfite and were treated using the EpiTect 
Bisulfite Kit (Qiagen) according to the manufacturer’s 
protocol. The Human Methylated & Non-methylated DNA 
Set (Zymo) was used to assess the efficiency of bisulfite-
mediated conversion of DNA.
To analyze the methylation in the TERT core 
promoter region, we performed PCR of bisulfite-
converted DNA using the following primer pair: 
forward primer 5’-gttggcgtttttgtattttgg-3’, reverse 
primer 5’-gaatacccgaatccccaat-3’. For the purpose of 
pyrosequencing, the primers were HPLC purified and the 
end of the reverse primer was biotin labeled. The PCR 
reaction mixture is 50 μl in volume, containing 25 μl 2X 
iTaq™ universal SYBR® Green supermix (BIO-RAD) 
with 200nM on each primer and 150ng of genomic DNA. 
PCR conditions used for the amplification were 95°C for 
3 min; 50 cycles of 95°C for 15 s, 60°C for 30 s and 72°C 
for 30 s. 2 μl of PCR product was run on 2% agarose gel in 
TBE stained with SYBR Gold Nucleic Acid Gel Stain. The 
remaining product was used for pyrosequencing. The three 
sequencing primers were as follows: 5’-tttttgtattttgggag-3’, 
5’-aagygyggtttagatt-3’, and 5’-ggtttttagtggatt-3’. The 
methylation percentage of each CpG site was presented 
and analyzed in a heat map.
Senescence-associated β-galactosidase analysis
β-galactosidase stain was performed using a 
senescence β-galactosidase staining kit (Cell signaling 
Technology). All the cell lines were harvested and washed 
with 1×PBS, and were then fixed overnight at room 
temperature in fixative solution. We used cytospin to 
make cell slides and then immediately covered the cells by 
adding β-galactosidase staining solution on the slides. All 
the slides were incubated at 37ºC (without CO2) overnight. 
Positively stained cells (dark blue) were counted in at least 
five microscopic fields with almost 500 counted cells. The 
ratio of the stained cells to the total number of cells was 
expressed as the percentage of senescent cells.
Statistical analysis
Statistical analysis was performed using Microsoft 
Excel (Microsoft, Redmond, WA, USA) and SAS version 
9.2 software (SAS Institute Inc., Cary, NC, USA.). 
Continuous data was presented as means plus/minus the 
standard deviation (±SD) and compared with the Student’s 
t-test. Statistical significance was defined by a two-tailed 
p-value of 0.05.
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